Inherited resistance to activated protein C (APC resistance) is an important risk factor of venous thrombosis. It is caused by a point mutation in the gene coding for coagulation factor V, called FV:Q506. Arterio-venous thrombosis is a common and serious medical problem in patients with systemic lupus erythematosus (SLE). We studied the prevalence of the factor V mutation associated with APC resistance and IgG anticardiolipin antibodies (aCLs) in an epidemiological cohort of 78 Swedish SLE patients, to determine their roles as risk factors for thrombosis. In addition, a detailed evaluation of the clinical manifestations in these patients was performed. Totally, 19 (24%) of the 78 SLE patients had thrombosis, 11 (14%) had venous thrombosis and 8 (10%) had a cerebral infarction caused by occlusion of cerebral vessels. Twenty-six (33%) SLE patients were aCL positive and 8 (10%) were heterozygous for the factor V mutation. Only one of the patients with venous thrombosis and one of the patients with cerebral thrombosis had the FV:Q506 mutation, whereas 3 patients with venous thrombosis and 5 patients with cerebral infarction were aCL positive. Eleven of 19 patients with heart valve disease were aCL positive, a statistically significant association (P = 0.01). In conclusion, we found no statistically significant association between venous thrombosis and FV:Q506 mutation or venous thrombosis and aCL positivity. There was, however, an association between heart valve disease and aCL positivity.
Dahlbäck B.The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res1995; 77: 1-43.
2.
Shen L., Dahlbäck B.Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem1994 ; 269: 18735-18738.
3.
Dahlbäck B., Carlsson M., Svensson PJFamilial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA1993; 90: 1004-1008.
4.
Griffin JH, Evatt BL, Wideman C., Fernandez JAAnticoagulant protein C pathway defective in a majority of thrombophilic patients . Blood1993; 82: 1989-1993.
5.
Koster T. et al. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet1993 ; 342: 1503-1506.
6.
Svensson PJ, Dahlbäck B.Resistance to activated protein C as a basis for venous thrombosis . N Engl J Med1994; 330: 517-521.
7.
Faioni EM et al. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost1993; 70: 1067-1071.
8.
Halbmayer WM , Haushofer A., Schön R., Fischer M.The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects . Blood Coagul Fibrinol1994; 5: 51-57.
9.
Zöller B., Dahlbäck B.Resistance to activated protein C caused by a factor V gene mutation . Current Opinion in Hematology1995; 2: 358-364.
10.
Bertina RM et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature1994; 369: 64-67.
11.
Sun X., Evatt BL, Griffin JHBlood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood1994 ; 83: 3120-3125.
12.
Greengard JA et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet1994; 343: 1362-1363.
13.
Voorberg J. et al. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet1994; 343: 1535-1536.
14.
Zöller B., Dahlbäck B.Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet1994 ; 343: 1536-1538.
15.
Zöller B., Svensson PJ, He X., Dahlbäck B.Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C . J Clin Invest1994; 94: 2521-2524.
16.
Kalafatis M. , Bertina RM, Rand MD, Mann KGCharacterization of the molecular defect in factor VR506Q. J Biol Chem1995; 270: 4053-4057.
17.
Koeleman Bpc , Reitsma PH, Allaart CF, Bertina RMActivated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood1994; 84: 1031-1035.
18.
Zöller B., Berntsdotter A., Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S . Blood1995; 85: 3518-3523.
19.
Vandenbroucke JP et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet1994; 344: 1453-1457.
20.
Hellgren M. , Svensson PJ, Dahlbäck B.Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives . Am J Obstet Gynecol1995; 173: 210-213.
21.
Fauno P. et al. Association between activated protein C resistance and postoperative deep vein thrombosis. Thromb Haemost1995; 73: 1371 (Abstract).
22.
Davies KA et al. Factor V Leiden mutation and venous thrombosis. Lancet1995; 345: 132-133.
23.
Matsuda J. et al. Resistance to activated protein C in systemic lupus erythematosus patients with antiphospholipid antibodies. Eur J Haematol1994; 53: 188-189.
24.
Hampton KK, Path Mrc, Preston FE, Greaves M.Resistance to activated protein C. N Engl J Med1994; 331: 130.
25.
Halbmayer WM , Haushofer A., Schön R., Fischer M.Influence of lupus anticoagulant on a commercial available kit for APC-resistance. Thromb Haemost1994; 72: 643-651.
26.
Gschwandtner ME, Lechner K., Pabinger I.Erroneously low APC ratio in patients with lupus anticoagulant. Ann Hematol1995; 70: 169-170.
27.
Pistiner M. et al. Lupus erythematosus in the 1980's: a survey of 570 patients. Semin Arthritis Rheum1991; 21: 55.
28.
Sturfelt G. et al. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. Medicine Baltimore1992; 71: 216-223.
29.
Jonsson H., Nived O., Sturfelt G.Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine Baltimore1989 ; 68: 141-150.
30.
Boumpas DT et al. Systemic Lupus Erythematosus: Emerging Concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med1995; 123: 42-53.
31.
Goodnight SHAntiphospholipid antibodies and thrombosis . Current Opinion in Hematology1994; 1: 354-361.
Feinstein DILupus anticoagulant, thrombosis and fetal loss . N Engl J Med1985; 313: 1348-1350.
34.
Khamashta MA et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med1995; 332: 993-997.
35.
Sturfelt G. et al. Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum1987; 30: 382-388.
36.
Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271-1277.
37.
Miller SA, Dykes DD, Polesky HFA simple salting out procedure for extracting DNA from human nucleated cells . Nucl Acids Res1988; 16: 1215.
38.
Dahlbäck B. , Nilsson IM, Frohm B.Inhibition of platelet prothrombinase activity by a lupus anticoagulant. Blood1983; 62: 218-225.
39.
Zöller B., He X., Dahlbäck B.Homozygous APC-resistance combined with protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost1995; 73: 743-745.
40.
Matsuda J. et al. Resistance to activated protein C activity of an anti-beta(2)-glycoprotein i antibody in the presence of beat(2)-glycoprotein I. Br J Haematol1995; 90: 204-206.
41.
Beuchamp NJ et al. High prevalence of mutation in the factor V gene within the U.K. population; relationship to activated protein C resistance and familial thrombosis. Br J Haematol1994 ; 88: 219-222.
42.
McNeil HP, Simpson RJ, Chesterman CN, Krilis SAAnti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA1990; 87: 4120-4124.
43.
Matsuura E. et al. Anticardiolipin antibodies recognize β 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med1994; 179: 457-462.
44.
Marciniak E. , Romond EHImpaired catalytic function of activated protein C and its cofactor protein S by antiphospholipid antibodies . Blood1989; 74: 2426-2432.
45.
Malia RG, Kitchen S., Greaves M., Preston FEInhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol1990; 76: 101-107.
46.
Nihoyannopoulos P. et al. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation1990; 82: 369-375.
47.
Reilly PA et al. Mitral stenosis in systemic lupus erythematosus. Successful management by mitral valve replacement. Eur J Cardiothorac Surg1988; 2: 377-379.
